Michael Barbella, Managing Editor11.07.22
Vektor Medical's vMap technology significantly reduces total procedure time, fluoroscopy use, and cost, according to new data.
Results from a retrospective, case-control study showed vMap reduced total procedure time by 68 minutes (227±54 vs. 295±77 minutes, p<0.001), reduced fluoroscopy time by 16.3 minutes (18.4±13.9 vs. 34.7±16.6 minutes, p<0.001), and cut EP lab costs ($2,267). The use of vMap was also associated with a reduced use of 64-electrode basket catheters in atrial fibrillation ablation cases (p=0.025).i
Conventional arrhythmia mapping is time intensive, expensive, and may require significant X-ray exposure, as invasive mapping requires a catheter to navigate throughout the heart. Invented by a team of physicians and engineers, vMap provides physicians the ability to non-invasively map potential arrhythmia source locations and guide non-invasive therapy planning for patients with cardiac arrhythmias.
“Physicians and engineers intentionally designed vMap to address shortcomings inherent to current mapping procedures, including risks from anesthesia and fluoroscopy exposure," said Avinash Toomu, UC San Diego Health. "These results signify a great step forward to address these challenges and add to the existing clinical body of evidence for vMap. I am delighted to be a part of the efforts to translate novel technologies to the clinical setting and help the many patients with cardiac arrhythmias.”
vMap is the first technology cleared by the U.S. Food and Drug Administration (FDA) to identify potential arrhythmia source locations anywhere in the heart using on the ECG in less than three minutes. In September 2022, Circulation: Arrhythmia and Electrophysiology published data validating the system’s accuracy in identifying nine atrial and ventricular arrhythmias and pacing types across all four heart chambers.
“These results show the positive impact vMap could have not only for patients, but also the doctors and hospital systems delivering care. We are particularly pleased that these results confirm our belief that vMap can reduce procedure time, fluoroscopy use, and cost associated with traditional mapping. These findings further demonstrate that vMap has the potential to alter the treatment paradigm for those experiencing arrhythmias,” Vektor Medical CEO Rob Krummen said. “As we continue forward, Vektor remains focused on improving outcomes for arrhythmia sufferers and continuing vMap’s commercial rollout to select cardiovascular centers of excellence across the country.”
vMap is designed to quickly, easily, and non-invasively map arrhythmia sources associated with focal- or fibrillation- type arrhythmias in all cardiac chambers, septum, and outflow tracts. The easy-to-use system takes less than three minutes for a clinician to input case information, upload and markup an ECG, and receive a 3D interactive arrhythmia source location map visualizing the inside and outside of the heart.
San Diego-based Vektor Medical Inc. developed the world’s first FDA-cleared forward-solution arrhythmia mapping technology to rapidly identify arrhythmia source locations using only 12-lead ECG data. This data is analyzed using proprietary computational modeling to create actionable 2D and 3D cardiac arrhythmia source probability maps. The company’s advanced, non-invasive cardiac arrhythmia mapping platform aims to improve the care of cardiac arrhythmias worldwide.
Reference
i Oesterlein T, Frisch D, Loewe A, Seemann G, Schmitt C, Dössel O, Luik A. Basket-Type Catheters: Diagnostic Pitfalls Caused by Deformation and Limited Coverage. Biomed Res Int. 2016;2016:5340574. doi: 10.1155/2016/5340574. Epub 2016 Dec 13. PMID: 28070511; PMCID: PMC5187596.
Results from a retrospective, case-control study showed vMap reduced total procedure time by 68 minutes (227±54 vs. 295±77 minutes, p<0.001), reduced fluoroscopy time by 16.3 minutes (18.4±13.9 vs. 34.7±16.6 minutes, p<0.001), and cut EP lab costs ($2,267). The use of vMap was also associated with a reduced use of 64-electrode basket catheters in atrial fibrillation ablation cases (p=0.025).i
Conventional arrhythmia mapping is time intensive, expensive, and may require significant X-ray exposure, as invasive mapping requires a catheter to navigate throughout the heart. Invented by a team of physicians and engineers, vMap provides physicians the ability to non-invasively map potential arrhythmia source locations and guide non-invasive therapy planning for patients with cardiac arrhythmias.
“Physicians and engineers intentionally designed vMap to address shortcomings inherent to current mapping procedures, including risks from anesthesia and fluoroscopy exposure," said Avinash Toomu, UC San Diego Health. "These results signify a great step forward to address these challenges and add to the existing clinical body of evidence for vMap. I am delighted to be a part of the efforts to translate novel technologies to the clinical setting and help the many patients with cardiac arrhythmias.”
vMap is the first technology cleared by the U.S. Food and Drug Administration (FDA) to identify potential arrhythmia source locations anywhere in the heart using on the ECG in less than three minutes. In September 2022, Circulation: Arrhythmia and Electrophysiology published data validating the system’s accuracy in identifying nine atrial and ventricular arrhythmias and pacing types across all four heart chambers.
“These results show the positive impact vMap could have not only for patients, but also the doctors and hospital systems delivering care. We are particularly pleased that these results confirm our belief that vMap can reduce procedure time, fluoroscopy use, and cost associated with traditional mapping. These findings further demonstrate that vMap has the potential to alter the treatment paradigm for those experiencing arrhythmias,” Vektor Medical CEO Rob Krummen said. “As we continue forward, Vektor remains focused on improving outcomes for arrhythmia sufferers and continuing vMap’s commercial rollout to select cardiovascular centers of excellence across the country.”
vMap is designed to quickly, easily, and non-invasively map arrhythmia sources associated with focal- or fibrillation- type arrhythmias in all cardiac chambers, septum, and outflow tracts. The easy-to-use system takes less than three minutes for a clinician to input case information, upload and markup an ECG, and receive a 3D interactive arrhythmia source location map visualizing the inside and outside of the heart.
San Diego-based Vektor Medical Inc. developed the world’s first FDA-cleared forward-solution arrhythmia mapping technology to rapidly identify arrhythmia source locations using only 12-lead ECG data. This data is analyzed using proprietary computational modeling to create actionable 2D and 3D cardiac arrhythmia source probability maps. The company’s advanced, non-invasive cardiac arrhythmia mapping platform aims to improve the care of cardiac arrhythmias worldwide.
Reference
i Oesterlein T, Frisch D, Loewe A, Seemann G, Schmitt C, Dössel O, Luik A. Basket-Type Catheters: Diagnostic Pitfalls Caused by Deformation and Limited Coverage. Biomed Res Int. 2016;2016:5340574. doi: 10.1155/2016/5340574. Epub 2016 Dec 13. PMID: 28070511; PMCID: PMC5187596.
